Parkinson's drug may weaken immunity: new study investigates

NCT ID NCT06634641

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether clozapine, a drug used to treat psychosis in Parkinson's disease, weakens the immune system over time. Researchers will measure immune markers in 24 patients before and after 6 and 12 months of treatment. The goal is to understand infection risks in this specific group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLOZAPINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

immunodeficiency disease inborn error of immunity Parkinson disease psychotic disorder Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLOZAPINE IMMUNODEFICIENCY PARKINSON'S DISEASE (PD) PSYCHOSIS

Contacts and locations

Locations

CHU Amiens-Picardie
RECRUITING

Salouël, 80480, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.